Vericel (VCEL) Capital Expenditures (2010 - 2026)
Vericel (VCEL) posted Capital Expenditures of $1.7 million for Q2 2026, up 18.28% sequentially from $1.5 million in Q1 2026, and down 78.75% YoY from $8.1 million in Q2 2025.
Analysis
Vericel (VCEL) Capital Expenditures (2010 - 2026) Analysis & Trends
Vericel has reported Capital Expenditures for 16 years, with the latest figure at $1.7 million in Q2 2026.
- Quarterly Capital Expenditures fell 78.75% year-over-year to $1.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.0 million (down 85.59% YoY) and the FY2025 annual result came in at $27.2 million, down 57.54% from the prior year.
- Capital Expenditures improved to $1.7 million in Q2 2026 per VCEL's latest filing, from $1.5 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $19.4 million in Q3 2024 and troughed at $1.4 million in Q4 2022.
- A 5-year average of $6.8 million and a median of $3.2 million in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2026: Capital Expenditures soared 514.24% in 2024, then tumbled 89.72% in 2026.
- Over 5 years, Capital Expenditures stood at $1.4 million in 2022, then soared by 479.08% to $7.8 million in 2023, then surged by 75.97% to $13.8 million in 2024, then tumbled by 84.14% to $2.2 million in 2025, then decreased by 20.99% to $1.7 million in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $1.7 million, $1.5 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 1.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.73 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 2.19 Mn |
| Sep 30, 2025 | 2.63 Mn |
| Jun 30, 2025 | 8.13 Mn |
| Mar 31, 2025 | 14.21 Mn |
| Dec 31, 2024 | 13.79 Mn |
| Sep 30, 2024 | 19.41 Mn |
| Jun 30, 2024 | 16.76 Mn |
| Mar 31, 2024 | 14.02 Mn |
| Dec 31, 2023 | 7.84 Mn |
| Sep 30, 2023 | 6.57 Mn |
| Jun 30, 2023 | 3.33 Mn |
| Mar 31, 2023 | 2.28 Mn |
| Dec 31, 2022 | 1.35 Mn |
| Sep 30, 2022 | 1.41 Mn |
| Jun 30, 2022 | 1.98 Mn |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 991,000.00 |
| Sep 30, 2021 | 2.46 Mn |